1. Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which.
A) Yes
2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
Bortezomib [Velcade] - 26
Carfilzomib [Kyprolis] - 0
Ixazomib [Ninlaro] - 10
Lenalidomide [Revlimid] - 13
Daratumumab [Darzalex] - 6
Melphalan, prednisolone and thalidomide (known as MPT) - 3
Cyclophosphamide, thalidomide and dexamethasone (known as CTD) - 1
Pomalidomide [Imnovid] - 4
* Please be advised that the data above is for the period 01/11/2019 to 29/02/2020. We are unable to provide for before this period due to a new Oncology system being implemented.
3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible how many CLL patients treated were new to therapy in the past 3 months?
A) 23 patients have been treated for the period 01/11/2019 to 29/02/2020.
4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR) - 1
Bendamustine and rituximab (known as BR) - 0
Ibrutinib [Imbruvica] -17
Chlorambucil - 0
Venetoclax - 2
Obinutuzumab - 3
Idelalisib - 0
Fludarabine and rituximab (known as FR) - 1
High-dose prednisone and rituximab - 0
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) -0
Alemtuzumab (Campath) with rituximab -0
* Please be advised that the data above is for the period 01/11/2019 to 29/02/2020. We are unable to provide for before this period due to a new Oncology system being implemented.
